New insights into HIV latent cells yield potential cure targets
Wednesday, July 27, 2022
Scientists described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research.
Novel HIV combination therapies could prevent viral escape and rebound
Tuesday, July 19, 2022
Carefully designed cocktails of broadly neutralizing antibodies (bNAbs) could help treat HIV while minimizing the risk of the virus escaping treatment, suggests a new study.
Best available therapy for AIDS-associated Kaposi sarcoma is cost effective in Africa
Friday, July 15, 2022
New research indicates the best available chemotherapy for Kaposi Sarcoma, which is infrequently used in Africa, is cost effective and would improve clinical outcomes.
Treating precancerous growths in people with HIV reduces anal cancer by more than half, study finds
Thursday, July 14, 2022
Researchers have shown that treating precancerous anal growths called high-grade squamous intraepithelial lesions (HSILs) in persons living with HIV significantly decreased the progression to anal cancer.
Immune system uses two-step verification to defend against HIV
Friday, July 8, 2022
A discovery could offer new methods for treating HIV, while uncovering the innate immune system's role in other diseases.
Imaging solves mystery of how large HIV protein functions to form infectious virus
Wednesday, July 6, 2022
Scientists have determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, or the process through which the virus propagates itself and spreads through the body. Importantly, determining the molecule's structure helps answer longstanding ...
HIV speeds up body's aging processes soon after infection, study shows
Friday, July 1, 2022
HIV has an 'early and substantial' impact on aging in infected people, accelerating biological changes in the body associated with normal aging within just two to three years of infection, according to new research.
Research reveals structure of a human endogenous reverse transcriptase
Thursday, June 30, 2022
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and other diseases, according to a study co-authored by a Rutgers researcher.
Common antiretroviral drug improves cognition in mouse model of Down syndrome
Tuesday, June 28, 2022
Lamivudine, a commonly-used antiretroviral drug for treating HIV, improves cognition in a mouse model of Down syndrome, according to the findings of a new study. Though clinical studies are necessary to confirm that the drug elicits a similar effect in humans, the findings pave the way for pharma...
A new technology offers treatment for HIV infection through a single injection
Monday, June 13, 2022
A new study offers a new and unique treatment for AIDS which may be developed into a vaccine or a one-time treatment for patients with HIV.
Risk of breakthrough COVID-19 infection after vaccination is higher among people with HIV
Tuesday, June 7, 2022
A new study finds that people with HIV have a higher rate of breakthrough COVID-19 infections after vaccination, compared to people without HIV.
Combination anti-HIV antibody infusions suppress virus for prolonged period
Wednesday, June 1, 2022
Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study. The findings suggest that combination bNAb...
A better understanding of HIV-1 latency
Tuesday, May 3, 2022
Researchers contribute to a better understanding of HIV-1 latency: implications for the development of new therapeutic strategies.
Helping prevent transmission of HIV from mother to child during breastfeeding
Wednesday, April 20, 2022
The antibody function known as antibody dependent cellular cytotoxicity (ADCC) and the ADCC sensitivity of HIV strains may influence the transmission of HIV from mother to child during breastfeeding. These data imply that enhancing ADCC, through a vaccine, for example, may not be sufficient to pr...
HIV: The antibodies of 'post-treatment controllers'
Thursday, April 14, 2022
A very small percentage of people with HIV-1, known as 'post-treatment controllers' (PTCs), are able to control their infection after interrupting all antiretroviral therapy. Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines...
New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial
Monday, April 11, 2022
A small phase I clinical trial has tested an anti-HIV strategy involving an adeno-associated viral vector-based gene delivery system that instructs cells to pump out antibodies that block HIV. In the trial of eight adults with HIV, the treatment was safe and well tolerated, and all participants p...
Antibiotic and antiretroviral drug effects on breast milk are explored for mothers living with HIV
Wednesday, April 6, 2022
Infants carry a vast assemblage of bacteria, viruses and fungi in their guts. Combined, these microbes make up a complex ecology known as the gut microbiome, which plays a major role in health and disease throughout life. The initial source of these billions of microbes is the mother's breast mil...
HIV drug stabilizes disease progression in metastatic colorectal cancer
Tuesday, April 5, 2022
Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line refractory metastatic colorectal cancer. These results provide evidence for the evaluation of reve...
CRISPR and HIV: New technique in human blood unveils potential paths toward cure
Friday, April 1, 2022
Scientists are using new advances in CRISPR gene-editing technology to uncover new biology that could lead to longer-lasting treatments and new therapeutic strategies for Human Immunodeficiency Virus (HIV).
'An underutilized tool:' UV-LED lights can kill coronaviruses and HIV with the flip of a switch, study finds
Tuesday, March 29, 2022
The same light bulbs used in offices and public spaces can destroy coronaviruses and HIV, according to a new study.